Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
International collaborative trial for relapsed and refractory acute lymphoblastic leukaemia
ISRCTN45724312Phase 3Completed
- Sponsor
- Manchester University NHS Foundation Trust
- Start
- Jan 2003
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of mitoxantrone and idarubicin in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Manchester University NHS Foundation Trust. Primary endpoints: Progression-free survival by risk group and MRD threshold utility at end of induction. Started Jan 2003; status: completed.
02
Drugs
mitoxantroneidarubicin
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ISRCTN45724312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN45724312.